Furthermore, on 27 June 2019, based on the results from the phase III REACH-2 trial [5], the human monoclonal antibody (mAb) against Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ramucirumab was approved for selected patients with HCC with serum alpha fetoprotein (AFP) of ≥400 ng/mL and who have been previously treated with sorafenib. This evidence concerns the gene AFP and hepatocellular carcinoma.